CinCor Pharma, Inc.
CinCor Pharma, Inc. (CINC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cinc · stock forecast · 7 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$73.00
Consensus
$48.50
+66.9% upside
Low
$30.00
Median: $45.5 · Last Close: $29.06
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$48.50
66.9% upside
High Target
$73
151.2%
Low Target
$30
3.2%
Current Price
$29.06
as of today
Based on analyst price targets, the CINC stock price prediction for the next 12 months ranges from $30 to $73. The consensus CINC price forecast of $48.50 implies 66.9% upside from the current price of $29.06.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $29.09 | ↑ 0.11% |
1-day model range: $29.07–$29.11. Peak: $29.11 (+0.11%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CINC · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-01-12 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2023-01-10 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-12-08 | Barclays | Maintains | Overweight→Overweight |
| 2022-12-07 | Barclays | Maintains | Overweight→Overweight |
| 2022-11-29 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2022-11-29 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2022-10-28 | Goldman Sachs | Maintains | Buy→Buy |
| 2022-09-09 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2022-08-22 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-08-09 | Morgan Stanley | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on CinCor Pharma, Inc. (CINC) stock. Of the recent 16 rating actions, 0 were upgrades and 3 were downgrades. 7 analysts currently cover CINC.
Analyst Recommendation Trends
CINC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast CINC EPS of $— for the current fiscal year, based on estimates from 0 analysts. The CINC revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CINC stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CINC price target is $48.50 (+66.9% upside), with an analyst consensus of Buy.
The CINC short-term stock prediction for tomorrow is $29.09 (+0.11%).
CinCor Pharma, Inc. trades on NASDAQ under the ticker CINC. The CINC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.
Frequently asked questions
CINC forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CINC price target is $48.50, with a high forecast of $73.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +66.9% potential upside from the current price of $29.06.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.